1. Home
  2. GERN vs CURB Comparison

GERN vs CURB Comparison

Compare GERN & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • CURB
  • Stock Information
  • Founded
  • GERN 1990
  • CURB 2024
  • Country
  • GERN United States
  • CURB United States
  • Employees
  • GERN N/A
  • CURB N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • CURB
  • Sector
  • GERN Health Care
  • CURB
  • Exchange
  • GERN Nasdaq
  • CURB NYSE
  • Market Cap
  • GERN 2.5B
  • CURB 2.5B
  • IPO Year
  • GERN 1996
  • CURB N/A
  • Fundamental
  • Price
  • GERN $3.66
  • CURB $23.77
  • Analyst Decision
  • GERN Strong Buy
  • CURB Buy
  • Analyst Count
  • GERN 10
  • CURB 5
  • Target Price
  • GERN $6.95
  • CURB $25.69
  • AVG Volume (30 Days)
  • GERN 9.5M
  • CURB 548.9K
  • Earning Date
  • GERN 11-07-2024
  • CURB 11-22-2024
  • Dividend Yield
  • GERN N/A
  • CURB N/A
  • EPS Growth
  • GERN N/A
  • CURB N/A
  • EPS
  • GERN N/A
  • CURB 0.06
  • Revenue
  • GERN $29,480,000.00
  • CURB $111,428,000.00
  • Revenue This Year
  • GERN $30,930.80
  • CURB N/A
  • Revenue Next Year
  • GERN $315.72
  • CURB N/A
  • P/E Ratio
  • GERN N/A
  • CURB $388.04
  • Revenue Growth
  • GERN 9199.68
  • CURB 52.36
  • 52 Week Low
  • GERN $1.64
  • CURB $18.80
  • 52 Week High
  • GERN $5.34
  • CURB $25.15
  • Technical
  • Relative Strength Index (RSI)
  • GERN 29.99
  • CURB N/A
  • Support Level
  • GERN $3.98
  • CURB N/A
  • Resistance Level
  • GERN $4.50
  • CURB N/A
  • Average True Range (ATR)
  • GERN 0.21
  • CURB 0.00
  • MACD
  • GERN -0.05
  • CURB 0.00
  • Stochastic Oscillator
  • GERN 3.45
  • CURB 0.00

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.

Share on Social Networks: